Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Antonio M. Risitano, J. C. Vallejo et al.|New England Journal of Medicine|2022Cited by 309
Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working PartyPedro Henrique Prata, Régis Peffault de Latour, Dirk‐Jan Eikema et al.|Blood|2023Cited by 2
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race StudyAntonio M. Risitano, Régis Peffault de Latour, S. Iacobelli et al.|Blood|2024Cited by 1
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia ReportPedro Henrique Prata, Régis Peffault de Latour, Simona Sica et al.|Haematologica|2025Cited by 0
<scp>Eltrombopag</scp> Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority <scp>EBMT</scp> ‐ <scp>SAAWP RACE</scp> StudyAntonio M. Risitano, Ghulam J. Mufti, Simona Iacobelli et al.|American Journal of Hematology|2026Cited by 0